Inquiry Basket
Loading ......
Avelumab is a fully human immunoglobulin gamma one (IgG1) monoclonal antibody that targets programmed death-ligand one (PD-L1), a critical immune checkpoint protein exploited by many cancers to evade immune-mediated destruction. Unlike other PD-L1 targeting antibodies that are humanized or chimeric, Avelumab retains a fully human Fc region that retains the ability to mediate antibody-dependent cellular cytotoxicity. This unique feature distinguishes Avelumab from other immune checkpoint inhibitors and may contribute to its clinical activity through dual mechanisms: blocking the PD-1/PD-L1 inhibitory pathway and directing immune effector cells to eliminate PD-L1 expressing tumor cells.The successful clinical use of Avelumab depends on accurate bioanalytical methods to support pharmacokinetic studies, immunogenicity assessments, and therapeutic drug monitoring. Reliable quantification of Avelumab concentrations in biological matrices is essential for understanding the relationship between drug exposure and clinical response, optimizing dosing regimens, and ensuring patient safety. Additionally, detection of anti-Avelumab antibodies is critical for evaluating the immunogenicity profile of this therapeutic antibody, as treatment-emergent anti-drug antibodies can alter pharmacokinetics, reduce efficacy, and potentially trigger adverse events.
Figure 1.Avelumab ELISA Kit.
The programmed death pathway is a central regulator of immune responses that maintains self-tolerance and limits excessive inflammation. Under normal physiological conditions, engagement of programmed death-one (PD-1) on activated T cells by its ligands PD-L1 or PD-L2 delivers an inhibitory signal that dampens T cell activity, preventing autoimmune tissue damage. Many cancers exploit this pathway by upregulating PD-L1 expression on tumor cells and tumor-infiltrating immune cells, creating an immunosuppressive shield that protects the tumor from immune-mediated destruction. PD-L1 is a transmembrane protein expressed on a wide range of cell types including tumor cells, antigen-presenting cells, and other immune cells within the tumor microenvironment. The interaction between PD-L1 and PD-1 triggers downstream signaling events that inhibit T cell proliferation, reduce cytokine production, and suppress cytotoxic activity. By co-opting this endogenous inhibitory mechanism, tumors evade immune surveillance and establish an environment that supports tumor growth, invasion, and metastasis.
Avelumab binds with high affinity and specificity to PD-L1, blocking its interaction with both PD-1 and CD80. By occupying the PD-L1 binding interface, Avelumab prevents engagement of PD-1 on T cells, thereby removing the inhibitory signal that would otherwise suppress anti-tumor immune responses. This PD-L1 blockade restores T cell function, enabling immune-mediated elimination of cancer cells. Unlike other PD-L1 targeting antibodies that have been engineered to reduce effector function, Avelumab retains a native IgG1 Fc region that can engage Fc gamma receptors on natural killer cells and other immune effector cells. This enables Avelumab to induce antibody-dependent cellular cytotoxicity against PD-L1 expressing tumor cells. In this process, Avelumab bound to PD-L1 on tumor cells recruits natural killer cells through Fc-Fc receptor interactions, triggering release of cytotoxic granules that kill the targeted tumor cell.
| Bioanalytical Monitoring of Avelumab | Details |
| Importance of Drug Quantification | Pharmacokinetic characterization describes the time course of Avelumab concentrations in the body following administration. Reliable quantification of drug concentrations in serum or plasma is essential for understanding the relationship between dose and exposure, evaluating the impact of patient characteristics on drug levels, and supporting dosing regimen optimization. Pharmacokinetic data from clinical trials inform product labeling and guide clinical use. The concentration of Avelumab in circulation is determined by the balance between drug input from intravenous administration and drug elimination. Elimination occurs through both target-mediated clearance involving binding to PD-L1 and non-specific clearance mechanisms such as proteolytic degradation and Fc receptor-mediated catabolism. The development of anti-Avelumab antibodies can accelerate elimination by forming immune complexes that are cleared more rapidly from circulation. |
| Immunogenicity Assessment | As with all biotherapeutic products, treatment with Avelumab may elicit immune responses resulting in the production of anti-drug antibodies. Anti-Avelumab antibodies can have clinically significant consequences including altered pharmacokinetics, reduced efficacy, and infusion-related reactions. Accurate detection and characterization of anti-Avelumab antibodies are therefore essential for understanding the clinical pharmacology of this therapeutic antibody. The incidence of anti-Avelumab antibodies in clinical trials is generally low, and most responses are non-neutralizing with low titers. However, immunogenicity assessment is required by regulatory agencies for all biotherapeutic products and must be performed using validated assays that are sensitive, specific, and capable of detecting clinically relevant anti-drug antibody responses. |
The Avelumab ELISA Kit is designed for the quantitative determination of free Avelumab concentrations in human serum, plasma, or other biological matrices. This kit is optimized for pharmacokinetic studies and therapeutic drug monitoring applications in clinical research and regulatory-compliant environments.
The Anti-Avelumab ELISA Kit is designed for the detection and semi-quantitative determination of anti-Avelumab antibodies in human serum, plasma, or other biological fluids. This kit is optimized for immunogenicity assessment in clinical research and regulatory-compliant environments.
Avelumab is a unique PD-L1 targeting antibody with a dual mechanism of action combining immune checkpoint blockade with antibody-dependent cellular cytotoxicity. This therapeutic antibody has demonstrated clinical efficacy in multiple cancer indications including Merkel cell carcinoma and urothelial carcinoma. Reliable bioanalytical methods are essential for supporting the clinical development and optimal use of Avelumab. The Avelumab ELISA Kit provides a validated, sensitive, and specific solution for quantifying free Avelumab concentrations in biological matrices, supporting pharmacokinetic studies and therapeutic drug monitoring. The Anti-Avelumab ELISA Kit enables comprehensive immunogenicity assessment, detecting anti-drug antibodies that could impact drug exposure, efficacy, and safety. Together, these kits provide a complete bioanalytical toolkit for researchers and clinicians working with Avelumab across all stages of development and clinical use. As immune checkpoint inhibitors continue to transform cancer treatment, reliable ELISA-based methods will remain essential for optimizing the use of these therapies in clinical practice.
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIAZ0042 | Avelumab ELISA Kit | 96T | Human | Quantitative | sELISA | Inquiry |
| DEIAZ0043 | Anti-Avelumab ELISA Kit | 96T | Human | Qualitative | sELISA | Inquiry |
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| Avelumab | CABT-ZB180 | Mouse Anti-Avelumab monoclonal antibody, clone 23I8 | Mouse | IgG1, | ELISA(cap) | Inquiry |
| Avelumab | CABT-ZB181 | Mouse Anti-Avelumab monoclonal antibody, clone 23H0 | Mouse | IgG1, | ELISA(det) | Inquiry |
| CD274 | CABT-Z703H | Human Anti-Human PD-L1 (Avelumab) Monoclonal Antibody, clone Avelumab [Biosimilar] | Human | IgG1, | FA | Inquiry |
| CD274 | DMAB-CDB25957 | Hi-Affi™ Recombinant Mouse Anti-Human PD-L1 Monoclonal antibody, clone Avelumab | Mouse | IgG | ELISA, FA, FC, IP, WB | Inquiry |
| CD274 | DMAB-CDB25958 | Hi-Affi™ Recombinant Rabbit Anti-Human PD-L1 Monoclonal antibody, clone Avelumab | Rabbit | IgG | ELISA, FA, FC, IP, WB | Inquiry |
Loading ......
